Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6MHP vaccine in advanced melanoma
NCT00089219Phase 2Completed
- Sponsor
- University of Virginia
- Start
- Jul 2003
- Primary completion
- May 2006
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of melanoma helper peptide vaccine in melanoma (3 arms), sponsored by University of Virginia. Primary endpoints: Dose-limiting toxicity and Immunogenicity at Day 22. Started Jul 2003; status: completed.
02
Drugs
melanoma helper peptide vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00089219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089219.